Last reviewed · How we verify
Deferoxamine mesylate only
Deferoxamine mesylate is an iron chelator that binds free iron and removes it from the body through urinary and fecal excretion.
Deferoxamine mesylate is an iron chelator that binds free iron and removes it from the body through urinary and fecal excretion. Used for Iron overload in patients with transfusion-dependent anemia, Secondary hemochromatosis.
At a glance
| Generic name | Deferoxamine mesylate only |
|---|---|
| Sponsor | The George Institute |
| Drug class | Iron chelator |
| Target | Ferric iron (Fe³⁺) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Deferoxamine forms stable complexes with ferric iron (Fe³⁺), preventing iron from participating in harmful oxidative reactions and tissue damage. The drug-iron complex is then eliminated renally and hepatically, reducing iron overload in patients with conditions such as transfusion-dependent anemia or hemochromatosis. This mechanism protects organs from iron-induced fibrosis and dysfunction.
Approved indications
- Iron overload in patients with transfusion-dependent anemia
- Secondary hemochromatosis
Common side effects
- Injection site reactions
- Hypersensitivity reactions
- Auditory toxicity
- Ocular toxicity
- Renal impairment
Key clinical trials
- The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL (PHASE3)
- ACT-GLOBAL Adaptive Platform Trial for Stroke (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Deferoxamine mesylate only CI brief — competitive landscape report
- Deferoxamine mesylate only updates RSS · CI watch RSS
- The George Institute portfolio CI